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Early detection of cancer
A B S T R A C T
A refinement of quality indicators (QIs) is described whereby the quality of care can be measured across
colposcopy services in different countries and healthcare settings.
A five-round Delphi process was conducted at successive satellite meetings from 2011 to 2015 of
leading European colposcopists to refine the most high-scoring QIs relevant to colposcopic practice. A
review and refinement of the wording of the standards and their criteria was undertaken by national
society representatives.
Six quality indicators were identified and refined. “Documentation of whether the squamocolumnar
junction (SCJ) has been visible or not” was changed into “for cervical colposcopy transformation zone (TZ)
type (1, 2 or 3) should be documented”. The standard “percentage of cases having a colposcopic examination
prior to treatment for abnormal cytology” was changed to “percentage of cases having a colposcopic
examination prior to treatment for abnormal cervical screening test”. The standard “percentage of all
excisional treatments/conizations containing CIN2+ (cervical intra-epithelial neoplasia grade two or worse)”
was changed into “percentage of excisional treatments/conizations having a definitive histology of CIN2+.
Definitive histology is highest grade from any diagnostic or therapeutic biopsies”. The standard “percentage of
excised lesions/conizations with clear margins” was unchanged. The remaining two QIs define the
minimum caseloads required for colposcopists. However, “cytology” was replaced by “screening results” to
acknowledge the introduction of human papillomavirus testing to European screening programmes.
Six QIs were identified to define good practice in colposcopy.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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European countries offer a variety of different screening concepts
from opportunistic to organized call and recall screening with an
ongoing shift to human papillomavirus (HPV)-based screening in
many countries and regions. Accordingly, the management of
abnormal screening results and the practice of colposcopy shows
a high heterogeneity throughout the continent. The European
Federation for Colposcopy (EFC) is the umbrella organization for 34
national colposcopy societies in Europe and neighbouring regions
(see Fig.1). During the EFC congress 2010 in Berlin there was a broad
consensus that on one hand colposcopy is the gold standard to
diagnose and guide treatment of high-grade cervical neoplasia but
on the other hand it performs badly without standards in education,
training and practice of colposcopy. For instance, before 2015 the
majority of treatments for cervical intraepithelial neoplasia (CIN)
performed in Francewere not performed undercolposcopic vision or
had a prior colposcopy [1]. In Germany patient management
including most treatments were performed without a pre-treatment
biopsy [2]. It was decided to establish EFC annual satellite meetings
between the three yearly scientific congresses. These aimed to
evaluate the differences in screening policy and practice of
colposcopy among EFC member countries and to develop a common
European standard of education, training and practice of colposcopy.
National member societies were invited to send their society
presidents or nominated deputies who were considered represen-
tative of and responsible for their society’s views.
During the first satellite meeting 2011, it became apparent that
well defined quality indicators were needed for the monitoring of
the quality of colposcopy in daily practice. The delegates
independently selected a number of possible indicators to measure
the quality of performing colposcopy, select patients for excisional
treatment, perform minimal invasive treatment and gain proof ofFig. 1. EFC memcure. These proposed quality indicators went through a five-round
Delphi consultation [3] which led to the original six EFC quality
indicators (QIs) listed in Table 1.
As quality assessment is a learning system, the EFC encouraged
the use and evaluation of the identified QIs in daily practice. A body
of unpublished work as well as the review of the German
colposcopy network (G-CONE) showed the principal utility of the
QIs as well as a need for revisions [4].
Materials and methods
During the subsequent 2013 and 2015 satellite meetings
criticism was raised by the review of Luyten et al. (2015) [4]
regarding a margin status standard which may encourage
inappropriately oversized excisions to achieve margins of excision
clear of CIN and so increase risk of subsequent preterm delivery in
young women [5]. There was further critique from unpublished
reviews and national societies which were collected, discussed
with delegates at each meeting and evaluated. These critical points
were clustered as:
1. The need to check for better arrangement of QIs so that the order
of presentation of these follows the pathway of care for
colposcopy patients from colposcopic examination to evalua-
tion of the excision specimens.
2. The need to check for more precise wording of QIs.
3. The need to check for more practicable criteria or targets for
achieving standards by reviewing the quality data available
from various practices across Europe.
4. The need to check for replacement of the QI “margin status”.
Modifications were proposed by national society representa-
tives or their societies, intensively discussed and either rejected,ber states.
Table 1
2011 EFC agreed 6 initial quality measures by Delphi process.
Quality indicator Target
1. documentation of whether the squamocolumnar junction has been seen or not (100%). 100%
2. % cases having a colposcopic examination prior to treatment for abnormal cervical cytology (100%). 100%
3. % excisional treatments/ conisations containing CIN2+ (85%). 80%
4. % excised lesions/ conisations with clear margins (80%). 80%
5. number of colposcopies personally performed each year for a low-grade/ minor abnormality on cervical cytology (>50). >50
6. number of colposcopies personally performed each year for a high-grade/ major abnormality on cervical cytology (>50). >50
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more than 80% of the member societies were represented by
delegates. All satellite meetings were moderated by members of
the EFC executive and detailed in meeting records, of which a
summary is available on the EFC website (https://efcolposcopy.eu/
efc-symposium-paris-11th-january-2017/). Each society had one
vote and votes were collected and counted during the meetings.
Changes to any QI needed a strong consensus although a minimum
percentage to define a strong consensus was not defined. In fact, all
of the subsequently listed modifications had the unanimous
support of delegates and were finally accepted at the EFC General
Assembly 2017, in Paris which was attended by 28 of the 34
member societies. Only Malta as an EFC member society failed to
attend any of the satellite meetings. Table 2 shows the timetable of
progress in agreeing QIs.
Results
1. It was decided to rearrange the QIs according to the pathway of
care during and after colposcopy. Therefore, the list of the QIs
starts with identification of the transformation zone and leads
through the process of colposcopy.
2. There was a broad consensus that rewording was necessary for
almost all QIs:
a “Documentation of whether the squamocolumnar junction (SCJ)
has been visible or not” was changed into “for cervical
colposcopy transformation zone (TZ) type (1, 2 or 3) should be
documented”. The new wording is clearly specific for cervical
colposcopy and excluded cases after hysterectomy. The
second part of the QI was changed to documentation of the
TZ type to harmonize with the International Federation of
Cervical Pathology and Colposcopy (IFCPC) nomenclature [6].
This was because delegates believed that the classification of
three TZ types demands higher alertness than the yes/no
statement of visibility of the SCJ regardless of whether or not
such a classification was reproducible amongst colposcopists
[7]. This is also relevant as the English colposcopy guidelines
has recommended adjusting loop length to correspond to TZ
type [8]. Overall this first QI was rated as most important for
all cases of cervical colposcopy in view of the relevance of the
TZ in the development of cervical pre-cancer and cancer for all
aspects of etiology, diagnosis and management of lesions.Table 2
Timetable of development of EFC quailty indicators.
Year Event Achievement 
2011 1. Satellite meeting Berlin Development of 37 possible quality i
2012 2. Satellite meeting
Berlin
Review of results 
2013 Publication of original EFC QIs 
2015 4. Satellite meeting
Brussels
Review of publications and critics. Co
2017 5. General assembly
Paris
Ratification of the revised QIs 
a Includes 25 societies at 1. Satellite meeting and 30 societies participating in the cob “Percentage of cases having a colposcopic examination prior to
treatment for abnormal cytology (100%)” was changed to
“percentage of cases having a colposcopic examination prior to
treatment for abnormal cervical screening test (100%)” because
of the shift towards screening based on HPV-testing in some
countries and regions in Europe. This QI is intended to protect
women from unnecessary treatment of abnormal screening
results without colposcopic evaluation.
c “Percentage of all excisional treatments/conizations containing
CIN2+ (cervical intra-epithelial neoplasia grade two or worse)
(85%)” was changed into “percentage of excisional treatments/
conizations having a definitive histology of CIN2+ (85%).
Definitive histology is highest grade from any diagnostic or
therapeutic biopsies”. The G-CONE review and reports from
national societies found a reasonable proportion of cases with
biopsy proven CIN2+ but no high-grade lesion in the definitive
excisional specimen. The lack of correlation between pre-
treatment biopsy and subsequent excisional treatment was
noted by Hopman et al. (1998) [9]. However, these cases were
considered as correct treatment by all delegates of the
satellite meetings and general assembly. Therefore, the above
rewording became necessary (see Table 3).
d “Percentage of excised lesions/ conizations with clear margins
(80%)” was the most discussed QI and the single QI without full
consensus. Although criticized as a potentially counterpro-
ductive indicator that may favour unnecessary large volume
excisions of the uterine cervix, it was the final majority
decision to leave the QI without any changes in wording.
e The remaining two QIs define the minimum caseloads required
for colposcopists. They remained basically unchanged but
because of the shift in screening programmes towards HPV
testing “cytology” was replaced by “screening results”.
3. Apart from the targets for the minimum caseloads all reviews
showed that the defined targets for QIs 1 to 4 were not
achievable in daily colposcopy practice (see Table 3). In the G-
CONE review, only single institutions reached some of the
targets, unpublished data from Italy and UK showed similar
findings. Proponents for reduced targets argued that only
feasible QIs could guide quality in daily practice (see Table 4).
National data could not be collected but institutional data from
Wolfsburg, Germany; Stoke, UK and Bari, Italy were obtained for
more than 15,000 cases. These data were presented at theNational societies involved
ndicators for subsequent Delphi consultation 39a
27
NA
nsensus revisions of 5 of 6 QIs. 32
28
nsultation and 4 associated and 5 possible member societies.
Table 3
Revised quality indicators, ratified by the EFC General Assembly 2017. Indicators are listed according to the timing of colposcopy based procedures. 1 = performance of
colposcopy, 2 = quality of indication before and 3 = quality of treatment, 4 = proof of cure. 5 and 6 are minimum numbers as a surrogate marker of experience.
Quality indicator Target
1. for cervical colposcopy transformation zone (TZ) type (1,2 or 3) should be documented. 100%
2. % of cases having a colposcopic examination prior to treatment for abnormal cervical screening test. 100%
3. % of excisional treatments/ conizations have a definitive histology of CIN2+. Definitive histology is highest grade from any diagnostic or therapeutic biopsies. 85%
4. % of excised lesions/ conizations with clear margins. 80%
5. number of colposcopies personally performed each year for a low-grade/ minor abnormality on cervical screening. >50
6. number of colposcopies personally performed each year for high-grade/ major abnormality on cervical screening. >50
Table 4
Performance of quality indicators from three member states.
UK (%) Germany (%) Italy (%)
Documentation of whether the squamocolumnar junction has been seen or not (100%) 93 95 99
% cases having a colposcopic examination prior to treatment for abnormal cervical cytology (100%) 100 94 98
% excisional treatments/ conisations containing CIN2+ (85%) 91 83 68
% excised lesions/ conisations with clear margins (80%) 25 73
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opposition of approximately half of the delegates who did
not want to compromise what they considered to be aspira-
tional targets. As a result, it was agreed that the EFC has no
objections with lower targets defined by national societies or
heath authorities who would like to use the EFC-agreed QIs for
certification and quality assurance procedures.
4. It was proposed to replace the QI 4 defining the percentage of
excisional specimens with clear margins. A systematic EFC
review shows that the EFC target of 80% is met only by a
minority of published trials and HPV testing is a better proof of
cure test and could replace clear margins for that purpose
without risk of overtreatment [10]. However, a majority of
delegates was neither requesting to have a lower target nor a
replacement of the complete QI.
Comment
Quality assessment is always an evolutionary process. While
defined QIs are needed to guide and assess quality, the QIs
themselves must be evaluated for appropriateness for routine
colposcopic practice. There is a need for an ongoing review to
adapt quality parameters whenever necessary. However, it seems
that as a result of the Delphi consultations and the EFC validation
process, five indicators of good colposcopy practice were found
that were feasible in daily practice, had broad acceptance from
Ireland to Georgia and Russia to Israel and seem to be universal
rather than just relevant to European practice. The single
exception was QI 4 (the percentage of excised lesions/conizations
with clear margins). An effort to obtain clear margins may
misguide clinical practice towards unnecessarily large excision
of the uterine cervix. Margin status of excision specimens has been
a proxy for success of treatment [10]. However, radicality of
treatment has varied over time with knowledge of known
complications of treatment. Increasing excision length is associat-
ed with significant increase in risk of preterm delivery. Having had
two or more loop conisations increases risk almost four times for
subsequent preterm delivery compared with no loop conisation
before delivery, and almost double the risk compared with one
loop before delivery [11]. On the other hand, Strander and
Adolfsson (2014) noted that an increased risk of cervical cancer
after long term follow-up as treatment for CIN had become less
radical over time [12]. Less hysterectomies, knife conisations and
more limited loop conisations for treatment may be to blamefollowing concern on poor obstetric outcome [13]. As a result of
this debate, the EFC supported a systematic review which
subsequently showed that HPV testing is a significantly better
predictor of cure than margin involvement with similar specificity
but better sensitivity [10]. It is very likely that this evidence will
lead to a revision of QI 4. We consider this process to be a good
example that the EFC’s strategy to achieve QIs via systematic
expert and Delphi consultations is useful and may identify areas
with broad consensus as well as areas in need of further
exploration of evidence.
Another criticism is that QIs should be achievable. Health
authorities and institutions who want to use the EFC QIs for
certification processes should be aware that the aims were
defined by expert colposcopists with an enthusiasm for the
method and reputations for clinical excellence in their area of
expertise. Therefore, apart from the minimum caseloads, the QIs
with percentage targets should be seen as ideal standards. During
the EFC general assembly 2017 in Paris, further alterations and
two additional QI measures were suggested but it was decided to
publish the consensus reached at previous satellite meetings.
Nonetheless, part of the consensus was that the given aims are
aspirational targets with regional or national services altering
these as considered appropriate to be used for regional or
national certification. The American Society for Colposcopy and
Cervical Pathology (ASCCP) published recently 11 colposcopy
standards that cover only the performance of colposcopy itself
without subsequent therapy. The EFC’s QI 1 was included, four
standards define maximum time to inform patients with high-
grade disease, while the remaining six standards regulate
reporting of colposcopy findings [14]. As the EFC is the roof
organization of more than 30 different countries with as many
different health systems, we focused our search on universal core
QIs and it is left to the national colposcopy societies to define
other QIs to regulate more details. Effective consensus has been
an evolution over six years. We have taken advice from senior
practitioners in a variety of healthcare settings with different
service demands. An assumption was that delegates were
representative of the wishes of their national societies but this
could not be validated. The next step is to make the QIs active to
drive improvement in care.
Data is needed for quality assurance and this must be collected
prospectively to be accurately validated and be exchangeable
between agencies. Freely interchangeable data will permit
comparison or benchmarking with others and so standardisation
of data collection is imperative.
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for quality assurance to occur including an agreed database,
standardised data with nominated personnel to provide the
organization of data collection and exchange to develop data
collation, data monitoring and analysis.
Conclusions
Although EFC QIs will undergo a continuing review and future
modifications seem very likely, we feel that at least six universal
indicators of good colposcopy practice have been identified as
concise measures of care. They should be useful to standardize
colposcopy management throughout and beyond Europe.
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